DUPIXENT is not a steroid. DUPIXENT is a biologic.
DUPIXENT 300 mg Q2W + INCS provided a 76% reduction in the need for SCS use and/or sinus surgery through Week 52 vs placebo + INCS (HR: 0.24 [95% CI: 0.17, 0.35]).1,4,a,b
DUPIXENT 300 mg Q2W + INCS provided a 74% reduction in the need for SCS use through Week 52 vs placebo + INCS (HR: 0.26 [95% CI: 0.18, 0.38]).1
aIndividually, SCS reduction and need for sinus surgery were not multiplicity-adjusted endpoints.4
b In SINUS-24 and SINUS-52, DUPIXENT 300 mg + INCS (Day 0: n=438; Week 24: n=376; Week 52: n=100); placebo + INCS (Day 0: n=286; Week 24: n=187; Week 52: n=61).1
CI, confidence interval; HR, hazard ratio; INCS, intranasal corticosteroid; SCS, systemic corticosteroid.